Challenge fuels change.
The Medable of today outpaces industry benchmarks and delivers game-changing results, fueled by a culture that thrives on progress and perseverance. As the industry shifts, we’re leading the way, not just as a product innovator, but as a partner invested in your success.
Delivery
85%
On-time go-live
Delivery
100%
On-time data transfers
Quality
90%
Patient eCOA adherence
Delivery
98%
Devices shipped on time
Help desk support
92%
First contact resolution
Delivery
5x
Faster study configuration
Delivery
35x
Faster first time eCOA creation than manual (no-code) build
Global access
120+
locales
“So proud of our collaboration which is positively impacting this space of the industry.”
GSK
Better today, ready for tomorrow
Product Innovation
By launching Medable AI, eCOA+, and Studio, we’ve streamlined trial execution, cut timelines by 50%, and automated critical tasks, empowering customers to focus on delivering life-changing therapies.
Process Excellence
Our sharpened focus on operational excellence has transformed how we deliver. With 98% device success and 95% on-time launches, we’ve built a foundation of precision and reliability to hit critical trial milestones seamlessly.
Partnership Culture
Through deep collaboration and patient-centric initiatives, we continue to build a culture of trust, innovation, and impact, ensuring every stakeholder benefits from meaningful progress.
Expanding access to life changing treatments.
Expanding global access
Medable currently operates in 70+ countries, enabling digital and decentralized trials worldwide, including regions such as Japan, France, and underserved remote areas.
Regional expertise and regulation support
Medable became the first U.S.-based clinical trial platform provider to receive approval from France’s Commission Nationale de l’Informatique et des Libertés (CNIL) for its eConsent and eCOA solutions for a partner Sponsor company.
Expertise and patient input across diverse therapeutic areas
Medable currently enables digital trials across 26 therapeutic areas and works with our expansive Patient Caregiver Network, which includes 90+ patient advocates and caregivers across 12 countries, representing 67 diverse health conditions.
Experience the award-winning platform designed for sponsors, sites, and participants.
Driving progress for sites, patients, and the industry.
Together with our partners and customers, we look forward to shaping the future of clinical research one breakthrough at a time to continue enabling treatments to patients faster.
Medable’s 2024 was a year of exceeding key milestones and helping our customers reach new heights. Take a look at the difference Medable has made with our year-end impact report.
Related content
Case study: Setting a new client standard in study closeout timelines
A top-10 global pharmaceutical company partnered with Medable for their pivotal Phase III diabetes study in the highly competitive market. Recognizing the inefficiencies in traditional study delivery and closeout processes, the company leveraged Medable’s expertise to accelerate timelines, enhance operational efficiency, and achieve a faster time to market for this high-profile therapy.
AI in Clinical trials - Key insights from industry experts
When OpenAI unveiled ChatGPT in November 2022, it ignited unprecedented interest in artificial intelligence. Three years later, generative AI and machine learning have caused seismic shifts in industries worldwide. The pharmaceutical industry is not left out of this shift, with Roots Analysis reporting that they expect AI within clinical trials to grow at a compound annual growth rate of 16% through 2035. This growth is driven by belief in AI’s unique ability to process and analyze massive datasets at groundbreaking speeds, identifying patterns and generating insights that would be impossible to discover through traditional methods. By leveraging these capabilities, pharmaceutical companies hope to fundamentally reimagine core aspects of clinical trials, from initial design through final data analysis.
Case study: Medable beats forecasted FPI date while raising eCOA adherence in Japan
A top-10 global pharmaceutical company aimed to address eCOA adherence and patient enrollment challenges faced by clinical trial sites and participants in Japan.
Recognizing Japan’s distinct regulatory, cultural, and logistical landscape, the company partnered with Medable todevelop an initiative to enhance the region’s patient and site experience.